Phase 3 Breast Cancer Trial, Recruiting (NCT06144164)

Phase 3 Breast Cancer Trial, Recruiting NCT06144164 Sponsor: Memorial Sloan Kettering Cancer Center Condition: Breast Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06144164 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Breast Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are female
People who have been diagnosed with breast cancer
People aged between 18 and 75 years
People who have agreed to a surgical procedure to remove lymph nodes from one underarm, or a smaller lymph node procedure that may lead to full lymph node removal

Who may not be able to join:

People who are male
People who do not speak English
People who the study garment does not fit
People whose breast cancer has returned in the underarm area
People who have previously had full underarm lymph node removal surgery
People who require lymph node removal from both underarms as part of their breast cancer treatment
People who are having only the smaller, limited lymph node procedure without the possibility of full lymph node removal
People who have a known severe allergic reaction to a specific dye called ICG, which is used in a procedure in this trial
People who have difficulty making their own decisions about participating

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 13 July 2026

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Michelle Coriddi, MD, Memorial Sloan Kettering Cancer Center

Phone: 646-608-8042

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06144164

Sponsor: Memorial Sloan Kettering Cancer Center

Phase: Phase 3

Status: Recruiting

Condition: Breast Cancer

Trial contact: 646-608-8042

More information: https://clinicaltrials.gov/study/NCT06144164

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are female
People who have been diagnosed with breast cancer
People aged between 18 and 75 years
People who have agreed to a surgical procedure to remove lymph nodes from one underarm, or a smaller lymph node procedure that may lead to full lymph node removal

Who may not be able to join:

People who are male
People who do not speak English
People who the study garment does not fit
People whose breast cancer has returned in the underarm area
People who have previously had full underarm lymph node removal surgery
People who require lymph node removal from both underarms as part of their breast cancer treatment
People who are having only the smaller, limited lymph node procedure without the possibility of full lymph node removal
People who have a known severe allergic reaction to a specific dye called ICG, which is used in a procedure in this trial
People who have difficulty making their own decisions about participating

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 13 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 3

Sponsor

Memorial Sloan Kettering Cancer Center

Registry

ClinicalTrials.gov

Start date

16 November 2023

Est. completion

16 March 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

The difference between the baseline and postoperative arm volume measurement

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov